Market Newsdesk

MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of date and time of management’s live presentation at the H.C. Wainwright 27^th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City, to Monday, September 8, at 5:00 PM Eastern Time.

Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event.

Details of the presentation are now as follows:

Event: H.C. Wainwright 27^th Annual Global Investment Conference
Date: September 8, 2025
Time: 5:00 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Contact

Patrick Gaynes
Corporate Communications
[email protected]

PHOENIX, Aug. 29, 2025 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share).

The dividend will be payable on September 30, 2025, to holders of record at the close of business on September 16, 2025.

About Global Water Resources

Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 systems which provide water, wastewater, and recycled water service. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix and Tucson. Global Water recycles over 1 billion gallons of water annually with 18.5 billion gallons recycled since 2004.

The company has been recognized for its highly effective implementation of Total Water Management (TWM). TWM is an integrated approach to managing the entire water cycle that involves owning and operating water, wastewater and recycled water utilities within the same geographic area in order to maximize the beneficial use of recycled water. It enables smart water management programs such as remote metering infrastructure and other advanced technologies, rate designs, and incentives that result in real conservation. TWM helps protect water supplies in water-scarce areas experiencing population growth.

Global Water has received numerous industry awards, including national recognition as a ‘Utility of the Future Today’ for its superior water reuse practices by a national consortium of water and conservation organizations led by the Water Environment Federation (WEF). The company also received Cityworks’ Excellence in Departmental Practice Award for demonstrating leadership and creativity in applying public asset management strategies to daily operations and long-term planning.

To learn more, visit www.gwresources.com.

Company Contact: Michael Liebman CFO and SVP Tel (480) 999-5104 Email Contact

Investor Relations Contact: Ron Both or Grant Stude Encore Investor Relations Tel (949) 432-7450 Email Contact

PETAH TIKVAH, Israel, Aug. 29, 2025 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a company developing and deploying transportation safety and advanced driver-assistance systems (ADAS) technologies and solutions, today presented its results for the first half ended June 30, 2025 and shared recent business updates.

Recent


Highlights

• SaverOne
  ’s
  execution of its international expansion
  strategy
  continues to
  gain momentum, with a number of wins in Europe bringing an ever-increasing number of international fleets;
• 5,43
  0
  systems have been ordered
  by customers as of today, of which approximately 4,160 have been installed;
• Sign
  ed
  new
  s
  ales and
  m
  arketing agreement
  in
  the United States and a distribution agreement in Canada, in addition to the existing agreements covering various countries in Europe and the United States;
• Signs
  preliminary agreement with l
  eading European ADAS
  t
  echnology
  p
  rovider for sensor fusion collaboration;

Financial Highlights


for the First Half of 2025

• Revenues increased 57% to NIS 756 thousand (~$224 thousand), compared with NIS 483 thousand (~$143 thousand) in the first half of 2024;
• Operating expenses were NIS 17.0 million (~$5.0 million) versus NIS 15.8 million (~$4.7 million) in the first half of 2024;
• Net loss was NIS 16.1 million (~$4.7 million) versus NIS 16.3 million in the first half of 2024 (~$4.8 million);
• Cash and cash equivalents as of June 30, 2025, increased to NIS 16.0 million (~$4.7 million).  

Management Comment

Commented Mr. Ori Gilboa, CEO of SaverOne, “2025 to-date has been a solid period of growth for SaverOne, driven especially by international expansion. In particular, we are expanding our global footprint by winning new deals with the international subsidiaries of long-standing customers, in line with our global expansion strategy.”

Continued Mr. Gilboa, “Our sensor solution to detect vulnerable road users (VRUs) such as pedestrians and cyclists, built upon our RF ADAS technology is also gaining further traction. We continue to engage in discussions with OEMs and tier-one suppliers, and in June we signed a preliminary agreement with a leading European-based automotive-technology ADAS provider, integrating our VRU detection solution within their ADAS sensor fusion platform, enhancing their sensor platform with non-line-of-sight VRU detection capabilities.”  

Concluded Mr. Gilboa, “Looking ahead, I am increasingly optimistic. I believe we are at a growth inflection point as we expand internationally, bringing an increasing number of fleets under the SaverOne protection umbrella.”

Recent Development


s


in the First Half of


2025

• SaverOne Broadened its relationship with Cemex in a number of countries in Europe including Germany, Spain, Czech Republic and others. The continued expansion into new Cemex fleets demonstrates the effectiveness of SaverOne’s international expansion strategy, targeting and expanding within companies with fleets throughout the world.
• SaverOne signed an agreement with Sdot Dan Regional Council to deploy the SaverOne System in its school bus fleet. Sdot Dan joins a group of other regional councils in Israel which aim to protect the transportation of students to local schools including Emek Yizrael, Mevo’ot Hermon and Mate Asher. This represents the growing recognition of leveraging technology for increasing safety of students by preventing driver distraction.
• SaverOne signed a sales and marketing agreement with Florida-based TOJ Jax targeting major US trucking fleets marking the third distribution agreement signed in North America including other agreements signed recently in Canada with MRF Geosystems, and Motor Supply in 2024 covering 10 southern US states. This represents a further key strategic step for SaverOne’s US growth plans, providing access to major fleet customers with thousands of vehicles.
• SaverOne was granted two new US patents: these patents out of SaverOne’s full IP portfolio of 23 demonstrate SaverOne’s technological leadership in mobile device detection and classification within vehicles. The new patents are entitled “System and Method for Classifying a Mode of Operation of a Mobile Communication Device in a Volume Based on Sensor Fusion” and “System and method for managing access to software applications on a mobile communication device via a phone location unit”.
• SaverOne signed a preliminary agreement with a leading European-based automotive-technology provider, dedicated to providing sensor solutions. This collaboration represents a new and important strategic step for SaverOne’s VRU detection roadmap. The collaboration will integrate SaverOne’s Vulnerable Road User (VRU) detection solution with its ADAS sensor fusion platform, introducing a non-line-of-sight VRU detection capability to this ADAS sensor fusion platform.
• SaverOne’s first distributor in the United States, Motor Supply, successfully completed its first pilot project with FedEx Trucking Contractor, MDM Trucking Express of Charlotte, North Carolina, and following rigorous testing, Motor Supply is moving forward with the installation of the SaverOne system across MDM’s entire fleet of 20 trucks.
• SaverOne signed its first distribution agreement in Canada with Calgary-based MRF Geosystems Corporation. The agreement includes a six-month exclusivity period in the Alberta province, during which MRF is expected to achieve sales of at least 1,000 units.

Financial Summary


for


the


First Half of


2025

Revenues increased 57% to NIS 756 thousand (~$224 thousand) in the first half of 2025 compared to NIS 483 thousand (~$143 thousand) for the first half of 2024. This increase was primarily due to the success of the Company’s efforts in penetrating global markets.

Gross profit was NIS 224 thousand (~$66 thousand), representing gross margin of 30% in the first half of 2025 compared to NIS 85 thousand (~$25 thousand), representing gross margin of 18%, in the first half of 2024.

Research and development expenses, net were NIS 9.8 million (~$2.9 million) in the first half of 2025 compared to NIS 8.9 million (~$2.6 million) in the first half of 2024.  

Selling and marketing expenses were NIS 2.4 million (~$719 thousand) in the first half of 2025 compared to NIS 2.4 million (~$714 thousand) in the first half of 2024.

General and administrative expenses were NIS 4.7 million (~$1.4 million) in the first half of 2025, compared to NIS 4.5 million (~$1.3 million) in the first half of 2024.

Operating
loss was NIS 16.8 million (~$5.0 million) in the first half of 2025, compared to NIS 15.7 million (~$4.6 million) in the first half of 2024. The increase was primarily as a result of somewhat increased R&D expenses and other operating expenses as the Company advances its efforts of establishing its footprint in global markets.

Net loss in the first half of 2025 was NIS 16.1 million (~$4.7 million), compared to NIS 16.3 million (~$4.8 million) for the first half of 2024.

Cash and cash equivalents and short-term bank deposits as of June 30, 2025, amounted to NIS 16.0 million (~$4.7 million), compared with NIS 13.3 million (~$4.0 million) as of December 31, 2024. The increase in the cash position was due to the Company’s securities purchase agreements with certain institutional investors and its sales of shares under this agreement.

The Company’s financial results are presented in accordance with IFRS as issued by the IASB.

*
Unless otherwise noted, for the purposes of the presentation of financial data, all conversions from New Israeli Shekels (NIS) to U.S. dollars and from U.S. dollars to NIS were made at the rate of NIS 3.
3
7
2
to $1.00, based on the representative exchange rate reported by the Bank of Israel on
June 30
,
2025
.

About
SaverOne’s
Systems 
SaverOne’s system is installed in vehicles to solve the problem of driver distraction as a result of drivers using distracting applications on their mobile phones while driving in a way that endangers their safety and the safety of their passengers. This phenomenon is considered one of the leading causes of global road accidents. According to the US National Highway Traffic Safety Administration, the annual cost of road accidents just in the United States stands at about $870 billion each year, excluding the costs of serious injury or death, with a quarter of those accidents estimated to be related to the use of the mobile phones while driving. SaverOne’s technology specifically recognizes the driver area in the vehicle. It prevents the driver from accessing distracting applications such as messaging while allowing others (navigation as an example) without user intervention or consent, creating a safer driving environment.

SaverOne’s primary target markets include commercial and private vehicle fleets interested in reducing potential damages and significant costs, vehicle manufacturers interested in integrating safety solutions into their vehicles, and insurance and leasing companies. SaverOne initially addresses car fleets with a focus on the Israeli, European, and US markets and other markets worldwide. SaverOne believes that an increased focus on monitoring and prevention of cellular distraction systems in vehicles, driven by upcoming expected EU regulation, will likely have a dramatic positive impact on the demand for its systems in the future.

The Company’s strategy is to provide its technology to customers in the aftermarket and address OEM vehicle manufacturers to integrate the Company’s protection technologies during the vehicle manufacturing process.

About SaverOne 
SaverOne is a technology company that designs, develops, and commercializes OEM and aftermarket solutions and technologies to lower the risk of and prevent vehicle accidents.

SaverOne’s initial product line is a suite of solutions that saves lives by preventing car accidents resulting from distraction from using mobile phones while driving. SaverOne is also developing a sensor system for early location and direction detection under all visibility conditions of vulnerable road users (VRU) through their cellphone footprint.

Learn more at https://saver.one/

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws that are subject to substantial risks and uncertainties. All statements, besides those of historical fact, contained in this press release are forward-looking. Forward-looking statements contained in this press release include but are not limited to, statements regarding SaverOne’s strategic and business plans, technology, relationships, objectives, and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations, and financial performance and condition and may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions. However, not all forward-looking statements contain these words. Forward-looking statements are based on SaverOne’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions about future events that may not prove accurate. Many factors could cause SaverOne’s actual activities or results to differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the ability of SaverOne’s technology to substantially improve the safety of drivers; SaverOne’s ability to protect its patented technology from infringement by third parties; SaverOne’s planned level of revenues and capital expenditures and its ability to continue as a going concern; SaverOne’s ability to maintain its listing on the Nasdaq Capital Market; the ability of SaverOne’s technology to substantially improve the safety of drivers; its ability to market and sell its products; its plans to continue to invest in research and development to develop technology for both existing and new products; SaverOne’s intention to advance its technologies and commercialization efforts in Europe and globally; acceptance of its business model by investors; the ability to correctly identify and enter new markets; the impact of competition and new technologies; general market, political and economic conditions in the countries in which SaverOne operates; projected capital expenditures and liquidity; SaverOne’s intention to retain key employees, and its belief that it will maintain good relations with all employees; a resurgence of the COVID-19 pandemic and its impact on business and industry; as well as other risks and uncertainties, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 21, 2025 and in subsequent filings with the SEC. Forward-looking statements in this announcement are made as of this date, and SaverOne undertakes no duty to update such information except as required under applicable law.

Investor Relations Contact:

Ehud Helft
+1 212 378 8040
[email protected] 

CONDENSED STATEMENTS OF FINANCIAL POSITION (New Israeli Shekels in thousands)
		As of June 30,								As of December 31,
		2025				2024				2024
		Unaudited								Audited
Assets
Current assets
Cash and cash equivalents			15,993				11,302				13,298
Trade receivables, net			1,728				1,290				1,621
Other current assets			762				1,247				1,686
Inventory			4,140				5,760				5,013
Total current assets			22,623				19,599				21,618
Non-current assets
Trade receivables, net			735				871				804
Property and equipment, net			192				211				229
Restricted deposits			216				216				216
Right of usage asset, net			761				1,142				951
Total non-current assets			1,904				2,440				2,200
Total assets			24,527				22,039				23,818
Current liabilities
Current maturities of leasing liability			469				469				469
Trade payables			1,471				3,695				1,826
Other current liabilities			2,598				2,037				2,991
Liability in respect of government grants			239				650				239
Derivative warrants liability			54				57				–
Promissory notes, net			1,665				3,912				6,336
Total current liabilities			6,496				10,820				11,861
Non-current liabilities
Leasing liability, net current			408				796				606
Liability in respect of government grants			811				801				721
Total non-current liabilities			1,219				1,597				1,327
Shareholders’ equity
Share capital and premium			192,051				150,353				169,949
Capital reserve in respect of share-based payment			11,428				11,163				11,229
Accumulated deficit			(186,667	)			(151,894	)			(170,548	)
Total shareholders’ equity			16,812				9,622				10,630
Total liabilities and shareholders’ equity			24,527				22,039				23,818

                

CONDENSED STATEMENTS OF COMPREHENSIVE LOSS (New Israeli Shekels in thousands, except per share and share data)
			Six Months Ended June 30,								Year Ended December 31,
			2025				2024				2024
			Unaudited								Audited
Revenues			756				483				1,683
Cost of revenues			(532	)			(398	)			(1,069	)
Gross profit			224				85				614
Research and development expenses, net			(9,840	)			(8,897	)			(19,397	)
Selling and marketing expenses, net			(2,425	)			(2,406	)			(4,796	)
General and administrative expenses			(4,742	)			(4,460	)			(9,673	)
Operating loss			(16,783	)			(15,678	)			(33,252	)
Financing expenses			(3,031	)			(1,242	)			(2,785	)
Financing income			3,695				636				1,099
Financing income (expenses), net			664				(606	)			(1,686	)
Loss for the period			(16,119	)			(16,284	)			(34,938	)
Comprehensive loss for the period			(16,119	)			(16,284	)			(34,938	)
Loss per share attributed to shareholders of Company, par value NIS 0.01 each
Basic and diluted loss per share:
Basic and diluted loss per share			(0.01	)			(0.21	)			(0.30	)
Weighted average of number of shares used to calculate the basic and diluted loss per share			1,217,701,006				79,171,297				117,908,475

CONDENSED STATEMENTS OF CASH FLOWS (New Israeli Shekels in thousands, except per share and share data)
		Six Months Ended June 30,								Year Ended December 31,
		2025				2024				2024
		Unaudited								Audited
Cash flow from operating activity
Comprehensive loss for the period			(16,119	)			(16,284	)			(34,938	)
Adjustments required to present cash flows from operating activities (Appendix A)			751				(31	)			532
Net cash used in operating activities			(15,368	)			(16,315	)			(34,406	)
Cash flows from investment activity
Change in restricted as to withdrawal			–				(5	)			(5	)
Purchase of property and equipment			(7	)			(10	)			(79	)
Net cash used in investment activity			(7	)			(15	)			(84	)
Cash flows from financing activity
Proceeds received from issuance of ADSs resulted from partial exercise of Commitment Amount under equity line			15,165				6,307				16,277
Net proceeds received from issuance of third and fourth promissory note			–				–				10,532
Repayment of government grants			–				–				(144	)
Net proceeds received from issuance of ADSs and warrants as part of shelf prospectus through public offering transaction			4,900				4,222				4,222
Repayment of principal in respect of leasing liability			(235	)			(117	)			(352	)
Exercise of restricted share units into ordinary shares			(*)-				(*)-				(*)-
Net cash provided by financing activity			19,830				10,412				30,535
Change in balance of cash and cash equivalents			4,455				(5,918	)			(3,955	)
Exchange differences on cash and cash equivalents			(1,760	)			108				141
Balance of cash and cash equivalents, beginning of period			13,298				17,112				17,112
Balance of cash and cash equivalents, end of period			15,993				11,302				13,298

(*)  Representing amount lower than NIS 1.

CONDENSED STATEMENTS OF CASH FLOWS (New Israeli Shekels in thousands, except per share and share data)
		Six Months Ended June 30,								Year Ended December 31,
		2025				2024				2024
		Unaudited								Audited
Appendix A – Adjustments required to present cash flows from operating activities
Income and expenses not involving cash flows
Depreciation			44				47				98
Amortization of right for use asset			190				129				320
Interest expenses in respect of leasing			37				50				95
Share-based payment to employees and service providers			255				388				598
Revaluation of derivative warrant liability and related expenses			(3,122	)			(217	)			(274	)
Recognition of discount, interest and exchange differences expenses related to Promissory Note			386				494				1,246
Finance expenses incurred from partial exercise of Commitment Amount under equity line			100				696				1,318
Exchange differences on cash and cash equivalent and restricted deposits			1,760				(108	)			(141	)
Changes in liability in respect of government grants			90				123				(224	)
			(260	)			1,602				3,036
Changes in asset and liability items
Decrease (increase) in other current assets			924				262				(177	)
Increase in trade receivables			(38	)			(56	)			(320	)
Decrease (increase) in inventory			873				(1,226	)			(479	)
Decrease in trade payables			(355	)			(608	)			(2,477	)
Increase (decrease) in other current liabilities			(393	)			(5	)			949
			1,011				(1,633	)			(2,504	)
			751				(31	)			532
Appendix B – Non-cash investment and financing activities
Repayment of promissory note (principal and interest) through issuance of ADSs resulted from partial exercise of Commitment Amount under equity line			5,057				3,721				12,581
Appendix C – Additional information pertaining to cash flows
Interest received			193				–				404

New partnership with Snow Consulting fuels significant performance improvements across key metrics

SCHAUMBURG, IL, Aug. 29, 2025 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of CardCash.com, Restaurant.com, and Takeout7.com, and a leader in the incentives and rewards industry, today announced significant year-to-date (YTD) growth in the affiliate marketing channel of CardCash.com, delivering 75% sales growth and substantial improvements across all key performance indicators.

Key year-to-date performance highlights compared to the prior year period:

• Sales increased by 75% compared to prior year period
• Affiliate commissions grew by 37%, reflecting enhanced partner performance
• Clicks per Impression surged by 130%, demonstrating significantly enhanced consumer engagement
• Orders per Click improved by 11%, evidencing higher conversion efficiency
• Average Order Value climbed by 51%, showing greater consumer spend per transaction

The strong performance reflects CardCash’s intensified focus on performance-driven affiliate partnerships and strategic use of data insights to optimize engagement and conversion rates.

“Our affiliate partners have always been integral to our growth, but this year we’ve truly prioritized and optimized this channel—and the results speak volumes,” said Carol Rosenblum, Marketing Manager at CardCash.com. “Through focused partnerships and strategic initiatives, we have dramatically improved consumer engagement and affiliate partner performance.”

CardCash recently partnered with Snow Consulting, an established leader in affiliate program management, to expanded affiliate opportunities and optimize program performance. The collaboration has rapidly advanced CardCash’s affiliate network, particularly within the high-growth travel sector where consumers are increasingly seeking cost-effective purchasing options.

“With economic pressures pushing consumers to be more budget-conscious, affiliate marketing is proving to be one of the most resilient and effective growth channels,” said Roger Snow, CEO of Snow Consulting. “CardCash is a perfect example of a brand that understands how to make affiliate partnerships work—not just for the business but for consumers as well. When you align strong performance marketing with genuine savings, you create a win-win scenario that drives sustainable success. The numbers we’re seeing here aren’t just a fluke; they show what happens when brands commit to the long game in affiliate marketing.”

The affiliate channel expansion aligns with broader consumer trends toward budget-conscious purchasing behavior amid ongoing economic pressures. The Company’s strategic focus on affiliate marketing complements its broader growth initiatives, including recent expansions into corporate rewards through the uChoose platform and enhanced restaurant technology solutions via the TakeOut7 acquisition.

For more information on CardCash’s affiliate opportunities, please visit [Website Link].

About Giftify, Inc.

Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Restaurant.com is the nation’s largest restaurant-focused digital deals brand, connecting digital consumers, businesses and communities by offering thousands of dining, retail and entertainment deal options nationwide at over 184,000 restaurants and retailers.

For more information, visit: www.giftifyinc.com, www.cardcash.com, www.restaurant.com and www.uchoose.cardcash.com.

Forward-Looking Statements

Press Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project,” “propose,” “plan,” “intend,” and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.

Investors Contacts: [email protected]

Strategic Launch with Zink Distributing Drives Exceptional Sell Through Results for American Rebel Light Beer Across Indiana

Nashville, TN, Aug. 29, 2025 (GLOBE NEWSWIRE) — American Rebel Light Beer (www.americanrebelbeer.com), the fastest-growing patriotic lifestyle beer in the U.S. and a division of American Rebel Holdings, Inc. (NASDAQ: AREB), officially rolled out in Indiana four weeks ago with Zink Distributing, delivering the brand’s most successful launch to date. In just under a month, American Rebel has achieved 10% market penetration in the Off-Premise channel—a standout performance in a beer market that’s trending downward nationwide.

Zink Distributing, founded in 2001, is the largest Anheuser-Busch wholesaler in Indiana, covering 16 counties including Marion, Hendricks, Hancock, Morgan, Vigo, Clay, Sullivan, Greene, and more. As the exclusive AB distributor for Indianapolis and surrounding regions, Zink is known for its operational excellence, retail execution, and commitment to community. With a portfolio that includes national brands and regional favorites, Zink has built a reputation for launching premium products with speed and scale—and American Rebel Light Beer is no exception.

“Zink Distributing didn’t just launch American Rebel—they lit a fire across Indiana,” said Todd Porter, President of American Rebel Beverage. “Their team executed with precision, passion, and a deep understanding of what it means to serve a patriotic crowd. This is the kind of launch that builds legends.”

Zink + American Rebel Light Beer: Accelerating Market Momentum

American Rebel Light Beer is gaining rapid traction across Indiana. In just four weeks, the brand has secured placements in hundreds of Off-Premise accounts throughout Zink Distributing’s territory, achieving 10% market penetration—a milestone typically reached only after multiple quarters of sustained effort. This early success highlights exceptional distributor execution, strong consumer demand, and a clear resonance with patriotic branding paired with premium taste. American Rebel’s velocity is outperforming regional benchmarks and generating repeat orders from retailers who are seeing immediate sell-through.

On-Premise Momentum

On-Premise accounts are also down nationally—but American Rebel is thriving. In Indiana, the brand is averaging 17 cases per point of distribution in bars, restaurants, and venues. That’s more than triple the volume seen in Off-Premise, signaling strong consumer pull and repeat velocity in high-traffic, high-engagement environments.

Stand Tall, Stand Proud and Be Loud – 16 oz Tall Boys Surge

American Rebel’s 16 oz “Stand Tall, Stand Proud and Be Loud” tall boys are leading the charge, accounting for nearly three-quarters of total volume sold since launch. Consumers are gravitating toward the bold packaging and larger format, making it a top seller in convenience stores, liquor stores, and high-energy bar venues. The tall boys are outperforming 12-pack 12 oz cans by a wide margin, and the momentum has prompted American Rebel to begin development of a 12-pack 16 oz format, slated to launch in spring 2026.

“When you crack open a 16 oz American Rebel, you’re not just drinking a beer—you’re standing for something,” said Andy Ross, CEO of American Rebel Holdings. “It’s bold, it’s loud, and it’s unapologetically American. That’s why it’s winning.”

Demand has been so strong that Zink Distributing has had to reorder tall boys to fill retail orders, after running out of product in their warehouse. The sell-through velocity has exceeded initial forecasts, with retailers requesting additional inventory to keep shelves stocked and cold boxes full.

Zink + American Rebel Light Beer: Accelerating Market Momentum at the 71st Annual Cornwell Quality Tools NHRA U.S. Nationals

Zink Distributing is playing a pivotal role in the successful launch of American Rebel Light Beer across Indianapolis, aligning retail expansion with the brand’s sponsorship of the 71st annual Cornwell Quality Tools NHRA U.S. Nationals. View the full press release Through strategic placements in top liquor stores and full-bar activations at Spykes, Rookies, and Raceway Pub, Zink delivered best-in-class coverage and velocity across 14 counties—solidifying American Rebel’s presence in the heartland.

American Rebel Light Beer: Crafted for Real American Taste

American Rebel Light Beer is brewed for drinkers who value freedom, flavor, and authenticity. With 110 calories, a crisp, bold taste, and no unnecessary additives, it’s a premium domestic light lager that delivers clean refreshment and strong consumer appeal. Whether it’s poured in a bar in Speedway or stocked on shelves in Terre Haute, American Rebel is built to perform in high-demand, high-pride markets like Indiana.

About American Rebel Holdings, Inc. (NASDAQ: AREB)

American Rebel – America’s Patriotic Brand (www.americanrebel.com) began as a designer and marketer of branded safes and personal security products and has since grown into a diversified patriotic lifestyle company with offerings in beer, branded safes, apparel, and accessories. With the launch of American Rebel Light Beer, the company has entered the beverage market to overwhelming success.

Learn more at American Rebel Beer

Watch the American Rebel Story as told by our CEO Andy Ross: The American Rebel Story

About American Rebel Light Beer

American Rebel Light is more than just a beer – it’s a celebration of freedom, passion, and quality. Brewed with care and precision, our light beer delivers a refreshing taste that’s perfect for every occasion. Since its launch in September 2024, American Rebel Light Beer has rolled out in Tennessee, Connecticut, Kansas, Kentucky, Ohio, Iowa, Missouri, North Carolina, Florida, Indiana, Virginia, Mississippi and now, Minnesota.

For more information about the launch events and the availability of American Rebel Beer, please visit American Rebel Beer or follow us on social media platforms @AmericanRebelBeer.

Rebel Light is a Premium Domestic Light Lager Beer – all-natural, crisp, clean and bold with a lighter feel. At approximately 100 calories, 3.2 carbohydrates, and 4.3% alcoholic content per 12 oz serving, it delivers a lighter option for those who love great beer but prefer a more balanced lifestyle. It’s brewed without added supplements and doesn’t contain rice or other sweeteners typically found in mass-produced beers.

Media Inquiries

Matt Sheldon
[email protected]
917-280-7329

Distribution Opportunities

Todd Porter
President, American Rebel Beverage
[email protected]

Investor Relations

[email protected]

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. American Rebel Holdings, Inc. (NASDAQ: AREB; AREBW) (the “Company,” “American Rebel,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include benefits of our continued sponsorship of high profile events, success and availability of the promotional activities, our ability to effectively execute our business plan, and the Risk Factors contained within our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the three months ended June 30, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

Attachment

• American Rebel Holdings Inc

SHENZEN, China, Aug. 29, 2025 (GLOBE NEWSWIRE) — Fangdd Network Group Ltd. (NASDAQ: DUO) (“FangDD” or “the Company”), a customer-oriented property technology company in China, today announced its unaudited financial results for the six months ended June 30, 2025.

First Half 2025 Financial Highlights

• Revenue for the six months ended June 30, 2025 increased by 45.3% to RMB203.4 million (US$28.4 million) from RMB140.0 million for the same period of 2024.
• Net loss for the six months ended June 30, 2025 was RMB39.2 million (US$5.5 million), compared to net income of RMB16.4 million for the same period of 2024.
• Non-GAAP net loss¹ for the six months ended June 30, 2025 was RMB39.2 million (US$5.5 million), compared to non-GAAP net income of RMB16.4 million for the same period of 2024.

First Half 2025 Operating Highlights

• Total closed-loop GMV² facilitated on the Company’s platform increased by 27.3% to RMB8.0 billion (US$1.1 billion) for the six months ended June 30, 2025 from RMB6.2 billion for the same period of 2024. The growth of closed-loop GMV was mainly attributed to supportive government policies, improving market conditions in China’s real estate sector, and the Company’s strengthened focus on development of its core projects and in-depth cooperation with reputable developers.

Mr. Xi Zeng, Chairman and Chief Executive Officer of FangDD, commented, “In the first half of 2025, with continuous policy support, China’s real estate market showed signs of stabilization despite ongoing adjustments. According to National Bureau of Statistics of China, the sales area of new property in the first half of 2025 decreased by 3.5% year-over-year, and the sales revenue dropped by 5.5% year-over-year. The decline rate narrowed significantly compared with the same period of 2024, indicating that the market is gradually bottoming out. Amid this environment, FangDD has been strengthening development of core projects and in-depth cooperation with reputable developers and business partners. As a result, the GMV and revenue have both increased simultaneously. Meanwhile, the company is also continuously exploring and innovating in new business areas. Looking forward to the second half of the year, we expect ongoing policy support and improving financial conditions to further support industry recovery. The company will also continue to optimize costs and upgrade business structure to achieve balanced growth in scale and profit, and promote higher-quality development.”

First Half 2025 Financial Results

REVENUE


Revenue for the six months ended June 30, 2025 increased by 45.3% to RMB203.4 million (US$28.4 million) from RMB140.0 million for the same period of 2024. This increase was mainly attributed to our commitment to deepening our core projects and establishing long-term stable business relationships with upstream and downstream partners. Additionally, a series of supportive policies, such as greater access to credit and funding for real estate developers, mortgage interest rate cuts, and lower down payments for home buyers, contributed to the improved real estate market.

COST OF REVENUE


Cost of revenue for the six months ended June 30, 2025 increased by 51.0% to RMB184.9 million (US$25.8 million) from RMB122.5 million for the same period of 2024. As our revenue increased, the commission fees paid to agents for their services in completing real estate transactions also increased proportionally.

GROSS PROFIT AND GROSS MARGIN


Gross profit for the six months ended June 30, 2025 increased by 5.7% to RMB18.5 million (US$2.6 million) from RMB17.5 million for the same period of 2024. Gross margin for the six months ended June 30, 2025 was 9.1%, compared to 12.5% for the same period of 2024. The decrease in gross margin was mainly due to a lower contribution from higher-margin value-added services.

OPERATING EXPENSES


Operating expenses for the six months ended June 30, 2025, which included nil share-based compensation expenses, increased by 4.8% to RMB90.2 million (US$12.6 million) from RMB86.1 million for the same period of 2024, which included share-based compensation expenses of RMB10.0 thousand.

• Sales and marketing expenses for the six months ended June 30, 2025 increased to RMB3.9 million (US$0.5 million) from RMB0.5 million for the same period of 2024. This increase was primarily due to the increased marketing costs in order to support our revenue growth.

• Product development expenses for the six months ended June 30, 2025 slightly increased to RMB12.7 million (US$1.8 million) from RMB12.0 million for the same period of 2024.
• General and administrative expenses for the six months ended June 30, 2025 remained at RMB73.6 million (US$10.3 million) as for the same period of 2024.

NET LOSS/INCOME

Net loss for the six months ended June 30, 2025 was RMB39.2 million (US$5.5 million), compared to net income of RMB16.4 million for the same period of 2024.

Non-GAAP net loss for the six months ended June 30, 2025 was RMB39.2 million (US$5.5 million), compared to non-GAAP net income of RMB16.4 million for the same period of 2024.

NET LOSS/INCOME PER SHARE


Basic and diluted net loss per share for the six months ended June 30, 2025 were RMB12.7 (US$1.8) and RMB9.7 (US$1.4), respectively. In comparison, the Company’s basic and diluted net income attributable to ordinary shareholders per share for the same period of 2024 were both RMB46.3.

LIQUIDITY


As of June 30, 2025, the Company had cash and cash equivalents, restricted cash, and short-term investments of RMB188.1 million (US$26.3 million). For the six months ended June 30, 2025, net cash used in operating activities was RMB21.2 million (US$3.0 million).

Exchange Rate

This press release contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars, in this press release, were made at a rate of RMB7.1636 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on June 30, 2025. The Company makes no representation that the Renminbi or U.S. dollar amounts referred could be converted into U.S. dollar or Renminbi, as the case may be, at any particular rate or at all.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income (loss) from operations, non-GAAP operating margin, non-GAAP net income (loss) and non-GAAP net margin by excluding share-based compensation expenses from income (loss) from operations and net income (loss). The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. Using the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future and are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. These non-GAAP financial measures should be considered in addition to financial measures prepared under GAAP, but should not be considered a substitute for, or superior to, financial measures prepared under GAAP. The Company compensates for these limitations by reconciling these non-GAAP financial measures to the most directly comparable U.S. GAAP measures, which should be considered when evaluating the Company’s performance. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

About FangDD

Fangdd Network Group Ltd. (Nasdaq: DUO) is a customer-oriented property technology company in China, focusing on providing real estate transaction digitalization services. Through innovative use of mobile internet, cloud, big data, artificial intelligence, among others, FangDD has fundamentally revolutionized the way real estate transaction participants conduct their business through a suite of modular products and solutions powered by SaaS tools, products and technology. For more information, please visit http://ir.fangdd.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “hope,” “going forward,” “intend,” “ought to,” “plan,” “project,” “potential,” “seek,” “may,” “might,” “can,” “could,” “will,” “would,” “shall,” “should,” “is likely to” and the negative form of these words and other similar expressions. Among other things, statements that are not historical facts, including statements about FangDD’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as FangDD’s strategic and operational plans, are or contain forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following. The general economic and business conditions in China may deteriorate. The growth of Internet and mobile user population in China might not be as strong as expected. FangDD’s plan to attract new and retain existing real estate agents, expand property listings, develop new products and increase service offerings might not be carried out as expected. FangDD might not be able to implement all of its strategic plans as expected. Competition in China may intensify further. All information provided in this press release is as of the date of this press release and are based on assumptions that the Company believes to be reasonable as of this date, and FangDD undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact

FangDD
Ms. Linda Li
Director, Capital Markets Department
Phone: +86-0755-2699-8968
E-mail:[email protected]

Fangdd Network Group Ltd. SELECTED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS DATA (All amounts in thousands of Renminbi, except for share and per share data)
	As of December 31,			As of June 30,
	2024			2025
Assets
Current assets
Cash and cash equivalents	75,351			34,647
Restricted cash	14,133			9,718
Short-term investments	113,632			143,729
Accounts receivable, net	196,041			166,385
Amounts due from related parties	–			8,346
Prepayments and other assets, net	144,081			91,956
Inventories	5,380			5,064
Total current assets	548,618			459,845
Total assets	731,189			679,002
Liabilities
Current liabilities
Accounts payable	180,737			102,125
Amounts due to related parties	23,900			29,975
Customers’ refundable fees	15,879			21,110
Accrued expenses and other payables	104,595			113,381
Convertible debt	–			9,737
Income taxes payable	139			200
Lease liabilities	1,332			606
Total current liabilities	326,582			277,134
Total liabilities	347,888			297,792
Total Fangdd Network Group Ltd. shareholders’ equity	386,344			380,189
Non-controlling interests	(3,043	)		1,021
Total shareholders’ equity	383,301			381,210
Total liabilities and shareholders’ equity	731,189			679,002

Fangdd Network Group Ltd. SELECTED UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) DATA (All amounts in thousands, except for share and per share data)
	For the Six Months Ended June 30,
	2024			2025
Revenue	139,969			203,394
Cost of revenues	(122,510	)		(184,942	)
Gross profit	17,459			18,452
Operating expenses
Sales and marketing expenses	(513	)		(3,856	)
Product development expenses	(11,958	)		(12,732	)
General and administrative expenses	(73,613	)		(73,625	)
Total operating expenses	(86,084	)		(90,213	)
Loss from operations	(68,625	)		(71,761	)
Net income/(loss)	16,411			(39,182	)
Net loss attributable to non-controlling interests	(974	)		(1,063	)
Net income/(loss) attributable to ordinary shareholders	17,385			(38,119	)
Net income/(loss)	16,411			(39,182	)
Other comprehensive income
Foreign currency translation adjustment	320			(598	)
Total comprehensive income/(loss), net of income tax	16,731			(39,780	)
Total comprehensive loss attributable to non-controlling interests	(974	)		(1,063	)
Total comprehensive income/(loss) attributable to ordinary shareholders	17,705			(38,717	)
Net income/(loss) per share*
– Basic	46.28			(12.66	)
– Diluted	46.28			(9.67	)
Weighted average number of ordinary shares used in computing net income/(loss) per share, basic and diluted*
– Basic	375,664			3,010,123
– Diluted	375,664			3,941,266

*Retrospectively restated to reflect the share consolidation effected on June 9, 2025, whereby every 16 ordinary shares of a par value US$0.0005625 per share were consolidated into 1 ordinary share of a par value US$0.009 per share.

Reconciliation of GAAP and Non-GAAP Results (All amounts in thousands, except for share and per share data)
	For the Six Months
	Ended June 30,
	2024			2025
GAAP loss from operations	(68,625	)		(71,761	)
Share-based compensation expenses	10			–
Non-GAAP loss from operations	(68,615	)		(71,761	)
GAAP net income/(loss)	16,411			(39,182	)
Share-based compensation expenses	10			–
Non-GAAP net income	16,421			(39,182	)
GAAP operating margin	(49.03	%)		(35.28	%)
Share-based compensation expenses	0.01	%		–
Non-GAAP operating margin	(49.02	%)		(35.28	%)
GAAP net margin	11.72	%		(19.26	%)
Share-based compensation expenses	0.01	%		–
Non-GAAP net margin	11.73	%		(19.26	%)

___________________
¹ Non-GAAP net income is defined as net income excluding share-based compensation expenses. For more information on these non-GAAP financial measures, please see the section captioned “Non-GAAP Financial Measures” and the tables captioned “Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this release.
² “Closed-loop GMV” refers to the GMV of closed-loop transactions facilitated in the Company’s marketplace during the specified period. Closed-loop transactions refer to property transactions in which the major steps are completed or managed by real estate agents in the Company’s marketplace.

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) — Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), formerly known as Blade Air Mobility, Inc. (Nasdaq: BLDE), today announced the successful closing of the previously announced divestiture of the Company’s Passenger business to Joby Aviation, Inc. (NYSE: JOBY). Joby has elected to pay the up-front consideration in stock. The Company may receive up to an additional $35.0 million in consideration based on maintaining certain employee retention and financial performance targets during the 18 and 12 months, respectively, following today’s closing, as well as the release of up to $10.0 million in indemnity holdbacks, payable in cash or stock at Joby’s election.

The Company’s re-branding to Strata Critical Medical is now complete and Strata will begin trading under the ticker symbol SRTA today.

“Our re-branding as Strata Critical Medical reflects the Company’s now 100% focus on the rapidly growing, contractual, and macro-non-correlated marketplaces for organ logistics and other medical services,” said Melissa Tomkiel, Co-CEO and General Counsel. “We’ve built the industry-leading organ transplant logistics and services platform, delivering rapid response times and cost efficiency while benefiting from the redundancy and unmatched scale of our coast-to-coast asset-light aircraft network.”

“Strata’s experience and track record providing mission-critical logistics to the organ transplant community provides the foundation for our growth plan in medical services and logistics more broadly,” said Co-CEO and CFO Will Heyburn. “Our ‘one-call’ logistics solution, where we procure a variety of additional services from third-parties on behalf of our customers, gives us a unique vantage point into a multitude of growth opportunities, which we will continue to pursue through organic growth, strategic partnerships and acquisitions, for which we are very well funded.”

Financial Outlook


As previously disclosed, we are updating our 2025 financial guidance to reflect the Passenger business divestiture throughout all periods in 2025. Beginning with our Q3 2025 earnings report, the Passenger business will be reported in discontinued operations.

For the full year 2025:

• Revenue of $160-170 million
• Double-digit Adjusted EBITDA(1)

Adjusted unallocated corporate expenses and software development costs are expected to decrease to a quarterly run rate of approximately $3.5 million in Q4 2025.

^{(1) We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.}

Investor Day


Strata is planning an investor day to take place this fall. We will provide more information about this event over the coming weeks.

About Strata Critical Medical

Strata Critical Medical provides time critical logistics solutions and specialized medical services to healthcare providers across the United States, strategically expanding its portfolio of services through acquisition and organic growth. Strata’s subsidiary, Trinity Medical Solutions, is an industry leader in air and ground transportation of human organs for transplant, leveraging Strata’s asset-light platform to reliably and efficiently deliver logistics solutions to its customers across the United States.

For more information, visit www.stratacritical.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as “will”, “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “target”, and “project” and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, relate to the sale of the Company’s Passenger business, analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to Strata’s future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning the impact and anticipated benefits of the sale of the Passenger business (including the receipt of any contingent consideration), the impact of such divestiture on Strata’s financial performance and liquidity outlook, the timing when such transaction may be completed, if at all, Strata’s future plans and business strategies, financial and operating performance (including the discussion of financial and liquidity outlook and guidance for 2025 and beyond), the composition and performance of its fleet, results of operations, industry environment and growth opportunities and new product lines and partnerships. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Strata’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: unexpected costs, charges, or expenses resulting from the recently completed divestiture; any failure to realize the anticipated efficiencies and benefits of such transaction; fluctuations in the value of any equity issued to Strata in the transaction; our continued incurrence of significant losses; failure of the markets for our offerings to grow as expected, or at all; our ability to successfully enter new markets and launch new routes and services; any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving our third-party operators; the impact of the recently completed sale of the Passenger business, any change to the ownership of our aircraft and the challenges related thereto; the effects of competition; harm to our reputation and brand; our ability to provide high-quality customer support; our ability to maintain a high daily aircraft usage rate; changes in economic conditions; impact of natural disasters, outbreaks and pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions or other circumstances on metropolitan areas and airports where we have geographic concentration; the effects of climate change, including potential increased impacts of severe weather and regulatory activity; the availability of aircraft fuel; our ability to address system failures, defects, errors, or vulnerabilities in our website, applications, backend systems or other technology systems or those of third-party technology providers; interruptions or security breaches of our information technology systems; our placements within mobile applications; our ability to protect our intellectual property rights; our use of open source software; our ability to expand and maintain our infrastructure network; our ability to access additional funding; our ability to identify, complete and successfully integrate future acquisitions; our ability to manage our growth; increases in insurance costs or reductions in insurance coverage; the loss of key members of our management team; our ability to maintain our company culture; our reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations; effects of fluctuating financial results; our reliance on third-party operators; the availability of third-party operators; disruptions to third-party operators; increases in insurance costs or reductions in insurance coverage for our third-party aircraft operators; the possibility that our third-party aircraft operators may illegally, improperly or otherwise inappropriately operate our branded aircraft; our reliance on third-party web service providers; changes in our regulatory environment; risks and impact of any litigation we may be subject to; regulatory obstacles in local governments; the expansion of domestic and foreign privacy and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses or maintain internal controls over financial reporting; our ability to maintain effective internal controls and disclosure controls; changes in the fair value of our warrants; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Strata undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.

Contacts

Mathew Schneider
[email protected]

SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:

• 2025 Wells Fargo Healthcare Conference
  Fireside Chat: September 5, 2025 at 8:00 a.m. ET
  Boston, MA

• H.C. Wainwright 27^th Annual Global Investment Conference
  Presentation: September 9, 2025 at 11:00 a.m. ET
  New York, NY

The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.

About
 
Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi ^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (“FDA”) approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (“EMA”) approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates.

CONTACTS 

Investors

[email protected]

650-260-7120 ext. 150

Media

[email protected] 
650-260-7120 ext. 150